-
Rontalizumab is a
humanized monoclonal antibody being developed by Genentech. As of November 2009[update], it is
being investigated in a
clinical trial...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
- alfa-2a
Peginterferon alfa-2b Antibodies:
Anifrolumab Faralimomab MEDI-545
Rontalizumab Sifalimumab Decoy receptors:
Bifarcept IFNGR (γ, II) Agonists: Interferon...
